Good day, and thank you for standing by. Welcome to the OraSure Technologies 2022 fourth quarter earnings conference call. At this time, all participants are in a listen only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you need to press star one one on your telephone. You will then hear an automated message advising you your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I will now like to hand the conference over to speaker today, Scott Gleason, Head of Investor Relations. Please go ahead. Thanks, Victor. Good afternoon and welcome to OraSure Technologies fourth quarter 2022 earnings call. I'm Scott Gleason, the SVP of Investor Relations and Communications, and presenting with me today for OraSure is Carrie Eglinton Manner, our President and Chief Executive Officer, and Ken McGrath, our Chief Financial Officer. As a reminder, today's webcast is being recorded and the recording can be found on the investor relations section of our website. Before we begin, you should know that this call may contain certain forward-looking statements, including statements with respect to revenues, expenses, profitability, earnings or loss per share, other financial performance, product development, performance, shipment and markets, business plans, regulatory filings, approvals, expectations and strategy. Actual results could differ significantly. Factors that could affect results are discussed more fully in the company's SEC filings, including its registration statements, its annual report on Form 10-K for the year ending December 31, 2021, its quarterly reports on Form 10-Q, and its other SEC filings. Although forward-looking statements help to provide complete information about our future prospects, listeners should keep in mind that forward-looking statements are based solely on information available to management as of today. The company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after this call. With that, I'm pleased to turn the call over to Carrie. Thanks, Scott, thank you to everyone for joining us today. In the fourth quarter, we once again delivered strong top-line results, which exceeded our prior financial guidance, generated cash of $9 million in the quarter, and made further progress in our strategic transformation journey. As we look to important aspects of how we are transforming, we have predominantly been focused on strengthening our foundation, expanding our cost reduction programs. Today, we announced a reduction in our non-production workforce of 11%. These changes better align our organizational structure with the realities of our business. We believe the restructuring allows us to utilize our COVID-19 cash generation to support incremental growth investments while targeting to achieve cash flow break even for the core business that is non-InteliSwab revenue by end of 2024. In 2023, we are focused on elevating growth across our core portfolio, increasing the reach of our current products, expanding segments, and further enhancing our enterprise capabilities to drive business efficiency and growth. As an early proof point in our strategy, we signed a deal with Quest Diagnostics to serve as the preferred provider of saliva collection kits for Quest's Genomic Sequencing Services Group's test offerings. We also have several co-clearances of sample collection devices underway with partner companies for their novel assays, similar to our recent Grifols' announcement. As we gain momentum across our business, we'll also look for opportunities to further accelerate growth through our own innovation pipeline, along with enhanced strategic partnerships as well as potential acquisitions. In order to provide more detail on our strategic progress, I'll begin with our organizational restructuring and efforts to drive core business profitability. First, we consolidated our two business units into One OraSure and have just announced the reduction of our non-production workforce by 11%. Streamlining our organization makes sense for our size and for the potential to unlock significant efficiencies, enhance collaboration while simplifying our leadership structure, increase revenue synergy opportunities, and improve resource allocation across the company. It will also allow us to leverage our enterprise functions such as manufacturing operations, R&D, quality and regulatory, along with our digital IT assets enterprise-wide. We anticipate the restructuring, along with other process improvements and cost reductions, will deliver operating expense savings of approximately $15 million per year when fully implemented at the end of the first quarter. As we lay the groundwork here for long-term cash generation, we have also made announcements. Sorry, and we have also made enhancements to our enterprise capabilities and manufacturing operations. I am pleased to announce that our new packaging and labeling configuration for InteliSwab has been authorized by the US Food and Drug Administration. We expect this new configuration to begin shipping by the end of this March. These changes have been a major undertaking by our team. Will drive per test cost savings of approximately $0.40. This includes the impact from lower shipping costs based upon the smaller packaging configuration, which will reduce total truckloads by approximately 50%. Furthermore, it will reduce our environmental impact since these changes will save on the order of 90 tons of plastic and 1,500 tons of paper from entering the waste stream. We are looking to apply these learnings to other portfolio products as well, such as our HIV self-test, as we believe we can unlock additional savings through further standardization and process enhancements. Contributing to our continuous process improvements, I'm pleased to share the addition of Trace Custer to our executive team leading quality and regulatory. Trace is a highly experienced life sciences industry veteran with leadership experience across numerous healthcare companies. Having joined us in Q4, Trace has now helped us implement a number of improvements, helped lead in our restructuring, and is evaluating further areas for efficiency, such as within our recent implementation of an electronic quality management system. On systems, I would also highlight that we have now fully launched Salesforce.com across our commercial teams. Using a standard CRM enables better monitoring and improvement of our sales KPIs, including in areas like pipeline growth and conversion success. I am a strong believer in operating rigor, and every one of our teams at OraSure now has established sets of leading and lagging key performance indicators to drive visibility and accelerate our success, each of which, along with those we roll up across the enterprise, we believe will drive results and deliver shareholder value. As I've mentioned repeatedly, our organization has strengthened our foundation and is increasingly focused now on elevating our core growth and our strategic transformation. This quarter, we established some early proof points that we believe help set the tone for our longer-term roadmap as we look to establish the company as a leader in self-testing and point-of-care diagnostics, as well as in effortless sample collection and services. First, within our diagnostics segment, we are working to expand our respiratory assay portfolio. Building on our success with COVID-19 lateral flow testing, we believe that InteliSwab will transition to become part of our core, and combination influenza tests will become an important diagnostic for two of the most widespread, clinically actionable, and serious respiratory viruses. As such, we are working internally and in partnership externally to address this healthcare need around the flu. While we are not yet prepared to share details, we do believe in the important role of this test as a part of the commercial expansion of our respiratory portfolio. Also in InteliSwab this quarter, we won two additional contracts from the U.S. federal government. On the first contract, the US Defense Logistics Agency agreed to purchase an estimated 18 million tests of InteliSwab COVID-19, with a maximum award of 36 million tests and a guaranteed minimum award of 3.6 million tests. The contract runs from November 2022 through November 2023. We were notified by the government of an incremental award of 3.2 million tests in December. Fulfillment of both of these awards has been running concurrently with our existing government contract that is supporting the school testing program. Under our federal government contract, we have shipped approximately 46 million tests as of the end of the fourth quarter and have up to 64 million additional tests which can be purchased, assuming the government orders the target number of tests under our second RFP win. In December, we were one of a group of companies awarded a tender for the state government of Connecticut, which also allows us to compete for up to 6 million additional tests. We think about growth drivers for diagnostics in 2023, we've also been notified that we will receive our first orders from Emory University supporting outreach testing under the Let's Stop HIV Together initiative. Our OraQuick in-home HIV test is now offered on Amazon.com directly with Prime Fulfillment. Our online sales via Amazon are relatively small, they are increasing as we fulfill more customer orders and have moved up in terms of search algorithm. We are also encouraged by recent U.S. government funding and future potential funding focused on healthcare conditions we serve. Moving to our molecular kits business, the headwinds we've discussed have continued as some of our key customers have taken a more cautious stance on their near-term business outlook. That said, we believe the fundamental backdrop supporting genetic sample collection remains very attractive as the number of applications continues to expand and precision health is key to the future of healthcare. Examples of these trends include the increase in high-value diagnostic and precision therapeutics, along with clinical laboratories increasingly working to reach patients in lower acuity settings, such as in-home and retail, and like the deal I mentioned with Quest. As we think about expanding our collection kits business, we would also highlight progress with Colli-Pee. This quarter, we launched four new CE-IVD products in women's health and beyond. Additionally, we have multiple clinical research and commercial co-clearance collaborations kicked off in an effort to continue establishing first void volumetric urine as a validated sample type for HPV screening, women's health therapeutics, and the detection of oncology biomarkers. Finally, I would point out the recent FDA approval of the first microbiome-based therapeutic to prevent C. difficile in adults with recent data showing that these therapeutics improve health outcomes. This approval paves the way for other biotherapeutics, and we believe will serve as a positive catalyst for microbiome-based investment in new research studies. In conclusion, we have made significant progress strengthening our foundation by resetting our cost structure and operating rigor. This progress will facilitate future growth investments and sets the stage for us to achieve cash flow breakeven by the end of 2024. As we look forward here in 2023, we are increasingly focused on elevating core business and increasing our innovation pipeline to accelerate profitable growth. With that, I am pleased to turn the call over to Ken to discuss our financial results and guidance. Thanks, Carrie. I'm pleased to discuss our financial results for the fourth quarter and provide updates on the financial outlook. First, from a top-line perspective, we delivered total revenue of $123.1 million in the fourth quarter, which was another new record for the company, representing year-over-year growth of 94%. Our diagnostics business unit delivered total revenue of $107.3 million in the quarter, growing 228% versus last year. The majority of this growth was driven by InteliSwab, which increased almost sixfold year-over-year, and our core diagnostics business was up 3% in the quarter. Core growth was negatively impacted by the timing of international orders, which were down on a year-over-year basis. Many orders were pushed out until the first quarter of 2023, and consequently, we expect a strong 1st quarter for our international diagnostics business. As Carrie mentioned, we will begin seeing our first orders under the Let's Stop HIV Together program in the 1st quarter, bolstering our domestic HIV business. Our molecular solutions business unit delivered revenue in the quarter of $15.8 million, declining 49% relative to the fourth quarter of last year. Excluding COVID-19 revenue, the business declined 32%. We continue to add new accounts, two of our large consumer-oriented customers and one large clinical lab ordered significantly less product when compared to Q4 of 2021. We believe this was due to a work-down of excess of inventory within these accounts as they respond to macroeconomic factors impacting the segments in which they compete. We also cycled against a significant research study purchase in 2021 that, despite ongoing needs, did not repeat in Q4 of 2022. Going forward, we expect to see continued volatility in this segment as some of our largest customers continue to deal with these macroeconomic factors. Despite this expected volatility, we remain optimistic about the potential to expand genetic testing through partnerships, such as the deal with Quest Diagnostics, and to support novel diagnostic assays while we also onboard new customers. From a gross margin perspective, our non-GAAP gross margins in the quarter were 40.7% compared to 40.0% last quarter and showing meaningful positive progress on a sequential basis. The sizable mix shift in revenue towards our diagnostic business unit continued to create some margin headwinds, with 87% of the revenue in the quarter coming from diagnostics versus 84% last quarter. We continue to make plans to boost our longer-term gross margin profile, including opportunities for further packaging improvements plus standardization across products, moving our legacy test automation as well as site consolidation based upon future volume contingencies. As Carrie mentioned earlier in the call, we plan to transition to our new packaging configuration for InteliSwab late in the first quarter of 2023, which we believe will save approximately $0.40 per InteliSwab test and have a meaningful impact on our gross margins. It is important to remember that given lower pricing under the new RFPs, we expect to have some pricing headwinds in the first quarter. Therefore, we anticipate some pressure on gross margins in the first quarter, followed by improvements throughout the year as mix and manufacturing efficiencies improve our cost structure. Moving on to our operating expenses. Our non-GAAP operating expense in the quarter of $31.8 million decreased by $3.5 million relative to the third quarter. The decline in operating expenses is attributable to timing and lower bad debt, along with our focus on cost controls. Looking forward, we believe the expected $15 million in annualized operating expense savings highlighted by Carrie will be fully recognized beginning in the third quarter of 2023. As part of achieving these savings from our workforce reductions, we expect to recognize one-time severance expense of $2 million in the first quarter. In anticipation of InteliSwab tapering in the second half of 2023, we will deliver further cost reductions in manufacturing operations. Across all of our cost reduction efforts, we are targeting to achieve cash flow breakeven in our base business, excluding InteliSwab revenue, by the end of 2024. Our operating expense savings will allow us to make targeted investments with attractive returns utilizing the significant cash we generated from InteliSwab in coming quarters. From a cash perspective, we ended the quarter with total cash and cash equivalents of $111 million, a $9 million increase from last quarter. Working capital increased significantly in the quarter, which the company believes will convert to cash as InteliSwab revenues taper in the future. We also continue to expect to generate positive cash flow from our $109 million Department of Defense contract to build out our InteliSwab capacity. The majority of the cash tied to this expansion has now been spent, and we will see positive cash flow as we complete milestones under the contract going forward. Given the continued volatility with InteliSwab, we are only providing quarterly guidance for the fiscal year. In the first quarter of 2023, we are guiding to revenues of $125 million-$130 million, representing year-over-year growth of 85%-92%. Regarding the cadence of revenue throughout the year, we are expecting continued strength in the InteliSwab revenues in the first half of the year while we deliver on our government contracts, followed by significantly more modest InteliSwab revenue in the third and fourth quarters. As Carrie mentioned, we are focused on driving momentum in our core business as we exit the year by implementing our planned cost savings and looking for opportunities to drive core growth throughout 2023. With that, I am pleased to turn the call back over to Carrie for concluding remarks. Thanks, Ken. We continued to make meaningful progress on our transformation journey this quarter as the company focuses on innovating and operating with disciplined execution and accountability. We have now firmly positioned the company on a strong financial footing and expect to see our balance sheet improve through 2023, creating the opportunity for future growth investments. Core growth is our predominant focus as an organization, and our team is motivated to deliver this year. We continue to believe that our capabilities can help power where healthcare delivery is going, meeting people, patients where they are, providing innovation and care at the lowest possible level of acuity. We are excited about the opportunities in front of us. With that, I'm pleased to turn the call back over to Scott for Q&A. Thanks, Carrie. Operator, we're now ready to begin the Q&A portion of the call. We would ask that you limit your questions to one question and one follow-up to ensure broad participation. As a reminder, to ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by while we compile the Q&A roster. Our first question will come from the line of Vijay Kumar from Evercore ISI. Your line is open. Hey, guys. Thanks for taking my question. Just on the base business here, I know I've shared all the color. Is the base business now at a place where it should grow or are we still looking at 2023 as a transition year in any color, I know you've spoken with the consumer genomics market macro, but you've also signed some new partnerships. Maybe just help us understand ex COVID what the base business revenues trajectory should look like? Yeah, no, great question, and thank you for that. In our guidance of $125 million to $130 million for Q1, what we're guiding towards is that the InteliSwab revenue will be roughly the same, roughly flat, or a little bit up, quarter over prior quarter. Implied in that is that our core business is roughly flat versus Q4. I'd add on molecular. You know, while we don't expect a snap recovery on the first half of 2023, we do remain optimistic about the long-term fundamentals of that segment. That, you know, we shared some positive signals like the deal with Quest. You know, it really is about those end segments. We are adding customers, and, you know, we are staying closely connected with them. While again, I just reiterate, we don't expect sort of the snap recovery, we do expect the strength and the long-term growth and that attractive market which, you know, which we continue to meet the needs of. Understood. Maybe my follow-up here, one on gross margins and free cash flows. Gross margin, slight improvement sequential, you know, from 3Q levels. Again, I think long term, we were looking at 50%+ as the gross margins of the business. Any comments on what the gross margin trajectory should look like? You've also mentioned free cash for base business, hitting free cash positive by end of fiscal 2024. Is the cash balance that you have on hand right now, that $80 million+, enough for you to achieve the free cash positivity? Hey, Vijay, thanks for the question there. You know, a couple things as we think about the margin profile of the business. You know, obviously, we've seen a very significant mix shift, you know, from molecular to diagnostics over the last 12 months. You know, eventually we're gonna get to the point where we would expect to see, you know, InteliSwabs, start to taper some. You know, we obviously made the comments in the press release where we talked about we expected the first half of the year to have a much higher weighting towards InteliSwab than the second half. You know, as that mix transition occurs, you will start to see some margin benefits because the molecular business has a higher underlying margin structure to it. You know, the other things that Ken mentioned that we're focused on is when you look at the manufacturing side, and, you know, we still have, you know, some significant changes that we're looking at in terms of site consolidation, standardization across products, and then also looking at things like some of the learnings from InteliSwab, you know, transferring that to the additional tests, which we think will drive margin improvements over time. It's something we're focused on. You know, we kinda see this as a marathon, you know, not as, you know, something that's gonna happen, you know, in any single quarter. It's something where we're gonna make continual process improvements. You know, we have a new SVP of Operations, Zach Wert, who's highly focused on, you know, driving efficiencies across our business, and it's something we're gonna keep working on, you know, throughout the year here. Yeah, from a cash perspective, as we mentioned, we increased cash quarter-over-quarter. One thing we did highlight is that our working capital increased over during Q4. A lot of that was ramping up for some of the government business as well as for the packaging changeover that we're doing. You know, if you look at it, I think our inventory quarter-over-quarter went up about $17 million and our accounts receivable went up about $9 million. We believe that's highly convertible to cash, given the government contract and the business that it's serving. Understood. Thanks, guys. Thanks, Vijay. Thanks, Vijay. One moment for our next question. Our next question comes from the line of Patrick Donnelly from Citi. Your line is open. Hi. This is Lizzie on for Patrick. Thanks for taking my questions. I guess first, I think you mentioned for some of the consumer-oriented customers, they were ordering less this quarter. I guess, how quickly do you suspect that they're gonna, you know, work through this inventory? Is this more of like a two quarter, you know, or is it more of like the second half of the year? Thanks. I have one follow-up. Yeah. Yeah, Lizzie, you know, I think what, you know, the guidance that we provided is that, you know, we're not gonna see kind of a snap recovery here, you know, in the, in the first half of the year. You know, that said, when we look at the end market growth, you know, for our core customers, you know, most of them are, you know, continuing to grow. You can see that, you know, among a lot of the clinical laboratories that you guys cover, that, you know, the end markets, you know, remain growing. You know, that's what makes us confident that, you know, some of the softness that we've seen, you know, is tied to inventory rebalancing. You know, we are seeing some labs, you know, having some financial challenges and so, you know, they're trying to preserve cash and so that activity is, you know, we believe translating to the business. So, you know, that gives us confidence in the longer term, but I think the bigger thing that Carrie mentioned is, you know, the fundamental backdrop we see for the market overall, you know, is exceptionally strong. You know, we've seen, you know, increased interest in, you know, people reaching patients where they are. You know, we had the Grifols deal last quarter. We had the Quest deal this quarter. You know, I think that's a strong example of, you know, the types of demand that we're seeing from customers, and we expect that to continue. It's something that we're gonna be focused on heavily this year as we focus on growth. Great. Thank you. Then I guess just on, your priorities when it comes to, you know, investing back in the business, you talked about site consolidation, standardization, and the new packaging. What are the other areas, I guess, that you're looking at, whether it's, you know, cutting costs or just investing internally? Thank you. Yeah, as you mentioned, our focus areas, first it's around InteliSwab, which we've delivered on over the past couple of quarters and continue to, with significant reductions in cost. In Q1, we'll see reductions, as we mentioned, in the packaging. Then the other area of focus will be around our facility site rationalization and really looking to optimize the footprint that we have, as well as and as Scott mentioned, taking the capabilities that we've developed with InteliSwab and transferring those to other product lines, and those efficiencies. Those are the primary focus areas. In addition to, as Carrie mentioned earlier, the restructuring that we announced earlier today. Those are the primary areas that we'll be focused on going forward. Thank you. Thanks, Lizzie. One moment for our next question. Our next question comes from the line of Brandon Couillard from Jefferies. Your line is open. Hey, thanks. Good afternoon. Hi, Brandon. Carrie, in terms of the restructuring, the 11% headcount reduction in non-production areas, I mean, should we think about those as mostly non-revenue generating positions? When you consolidate molecular and diagnostics together, will that change how you report the segment revenues externally? Lastly, the $15 million savings, should we think about that as a gross or net number? I think you kind of mentioned some desire to, you know, maybe reinvest some of that in growth. Is that more of a 2024 investments or should we see that sooner? Brandon, I'm gonna let Ken start on the segment reporting, and then I'll hit the restructuring piece. Yeah, Brandon, we are planning on starting in Q1 of 2023 to change our reporting to one segment, recognizing the changes that we've made in the organization structure and how we run the business as we go forward. As far as the cost savings, the $15 million annualized cost savings that we quoted, the way to think of it is, coupled with the cash that we've generated from InteliSwab and are generating from InteliSwab, and then layering on the cost savings, what we are doing is building up a cash base to then further invest in the business, whether it's organic investments or inorganic. Obviously, we can't talk about any specific examples on this call. That's the approach that we're taking is deliver on InteliSwab, to build up that cash base, and then become more efficient with the core business and use that savings then to reinvest in the business going forward. Again, that reinvestment will be organic areas as well as inorganic, depending on the best opportunities. Carrie, do you wanna add? I'd say, you know, focusing on strategic partnerships where those make sense now, we've talked about that from the beginning, and you will see us increasingly focusing on delivering growth through strategic partnership. On the restructuring, very clearly, we have restructured to generate growth, you know, so as to not impact that moving forward. I'd say when you look at the cost-cutting, it started with simplification, really focused around, you know, consolidating functions across the enterprise. We're too small a business to have, you know, sort of these distinct business units. Eliminating redundant management positions, you know, focusing on value creation opportunities. That consolidation of functions for a business our size just really, you know, makes a lot of sense. you know, it's now that we have done a lot of the work on strengthening the foundation, it really is about elevating our core growth. I just reiterate that innovation internally plus strategic partnerships as we rebuild our cash base to be even stronger. Yeah. Carrie, as you mentioned, coupled with the restructuring is also a focus on process improvements within the organization, to help drive our efficiency as we go forward. Got it. Okay. On InteliSwab, any chance you can give us a feel for the magnitude of the sequential gross margin improvement that you may have seen just for that product? What does the $0.40 of savings from the new packaging, you know, mean to the gross margin profile of that product? Yeah, I don't, I don't think we've given that level of detail out in our numbers, but I'll tell you how to think about it, right? Right now, I think we mentioned, there was 46 million tests delivered through December of last year and about 64 or so million tests remaining, going forward on the 3 contracts that we have. One element is some of those contracts have lower price points than the original contract. That's 1 headwind. However, to your point, as we offset that, you can think of the $0.40 per test being implemented by the end of this quarter. Based on the remaining volume of those tests, it's a simple math there. Scott, I think that's about what we've said publicly, correct? Yeah. You know, Ken, you know, obviously, Brandon, we've said the preponderance of our revenue is still under those government contracts, which the pricing's been disclosed. When you think about, you know, $0.40, you know, relative to that test pricing, obviously it's a very significant increase, you know, in the gross margin structure for that business. You know, on a sequential basis, while we didn't give the gross margins, we did see a meaningful improvement in terms of InteliSwab on a sequential basis as well. Got it. Thanks. I'll leave it there. Thank you. One moment for our next question. Our next question comes line of Jacob Johnson from Stephens. Your line is open. Hey, good evening, everybody. Just maybe the other side of the restructuring you announced today, the One OraSure initiative. Carrie, you mentioned the potential for enhanced collaboration and revenue synergies. Can you just talk about some of the opportunities you see as you unite the segments? Absolutely. You know, Jacob, I think we've shared some of the restructuring and expanded upon it in this quarter, that we brought together a product office, which brings together our commercial teams in sales and marketing, product management and R&D under Kathy Weber, whom you all know. The opportunity spans from our collection kits where we, you know, have tremendous relationships and can expand in through areas like new applications for those kits, microbiome services, building on our services capability of what, you know as our Diversigen business. I'd say, let me be clear that while we think there's opportunity to cross-sell more, we also through this restructuring, are very much maintaining the specialized strengths within our portfolios. Even though we're creating one product office, which allows for collaboration, there's also this element of best practice sharing. It's not that the sales teams are being mashed together to sell those products. It's more maintaining specialization, leveraging best practices, and sharing, you know, a strategic account focus across the business to increase our hunting while maintaining all of our service capabilities. Okay. That's helpful. Okay. Thanks, Carrie. Just for my follow-up, I think last quarter you mentioned inorganic growth opportunities. Ken just mentioned it, I think in the answer previously. Certainly understand you're not gonna tell me what you're going to buy, but in terms of maybe timing and your appetite for M&A, do you think you've accomplished a lot of maybe some of the operational internal organic initiatives, those sort of blocking and tackling such that now you can start looking, or do you feel like there's still some more things you need to do before you look to M&A? To your point, Jacob, there are still things internally we can and will do to increase our innovation pipeline. This focus on strengthen our foundation, we feel like puts us on very solid financial footing while we simultaneously increase our internal pipeline and all of the process rigor around that. I said it before, but I'm gonna emphasize again. Strategic partnerships are the way where we get momentum before we have the cash, because, you know, we're gonna be very judicious and not threaten any aspect of our liquidity. Strategic partnerships give us that way to think about how we can expand our value chain capabilities within each of our portfolios and then potentially position for the right M&A as it's available. While we're not talking specific M&A, I'd focus on strategic partnerships and value chain expansion in the segments in which we play. Understood. Thanks for taking the questions. Thanks. Thanks, Jacob. One moment for our next question. Our next question comes from the line of Andrew Cooper from Raymond James. Your line is open. Hey, everybody. Thanks for the question. Maybe first, just thinking about the gross margins. I know a couple have already sort of attacked this a little bit, when we think about InteliSwab margins being up sequentially, you had talked about the core being down a bit quarter-over-quarter, and that seems like it's what played out. Can you give us a sense for other than mix, what some of the moving parts are there? Did things perform, you know, more or less as you expected? And maybe just on a constant mix basis, what has that core gross margin really looked like, and how should we think about it trending through the course of 2023? Yeah, I think you're thinking of the right elements as you go through it. Mix, as Scott mentioned, as we mix towards more diagnostic, which has a overall lower margin than molecular over the past couple of quarters, that's kind of a headwind to overall gross margins. However, the team, through their great work, has offset a lot of that with the improvements in efficiencies, in particular for InteliSwab, and they will continue to do that, as we mentioned, with the packaging and freight reductions of about $0.40 per test as we go forward. I think you're thinking of the right elements in there. The other area that we've made improvements in margin is as we bring on more volume, we do better with our overall absorption in the facilities that we have. That's an area that we focused on, as well as a significant reduction in scrap along the way. I think you're thinking of the right areas. It's mix, then there's overall operational efficiency that we're driving. If you think long term, one of the areas that we mentioned on a prior question was around our facility footprint and really looking at leveraging our facility footprint going forward to take best advantage of it. Then in addition to that, to leverage the capabilities we've developed and built with InteliSwab, and leverage that on our other platforms. Those are the areas that's how we're thinking of it going forward. I think you're thinking of it the right way. Yeah. Brian, I would just highlight two other areas. You know, one thing we did see this quarter is we had a higher international mix when we look at our diagnostics segment. You know, the international diagnostics business has a lower gross margin profile than our U.S. domestic-based diagnostics. The other piece as we think about our margin structure that we saw in the quarter is remember the COVID molecular kits had a very high margin profile. It was the highest margin product, you know, for the company. As that's tapered some, that also has created some headwinds as well for the business overall. Okay. Helpful. Maybe following up on one of those things, just in terms of the facility footprint and how you think about that. Obviously, the government's funding a lot that can probably be used beyond InteliSwab. Should we be thinking about that as likely being some of the legacy facilities moving into that super factory you've talked about before? What does timeline sort of look like for that? Anything else we should think about from that footprint perspective? Yeah. At a high level, yes, you're right, that's how we're thinking of it. We haven't quoted any timelines at this point. You can imagine it's an urgency of us. We have a facility, we have a capability we've built. Now we wanna leverage that to its fullest extent. That's the analysis and approach we're looking at right now. I can't give you a timeline, but that is a sense of urgency. Yes. Site consolidation is a priority. Absolute priority. Those capabilities we have built, the super factory, Andrew, that you appropriately remember, can be translated across our OraQuick platform and leveraged more broadly in the portfolio. Okay, great. I'll stop there. Thanks for the questions. Thanks, Andrew. One moment for our next question. Once again, as a reminder, that's star one one for questions. Our next question comes from the line of Casey Woodring from JPMorgan Chase & Co. Your line is open. Hi, guys. Thanks for taking my questions. Hi, Casey. The stocking in genomics, is that a one quarter dynamic here, in 2023? Or is it perhaps something that you see lasting into the second half of the year? You know, how do you see stocking playing out through the course of this year? Do you see this business growing in 2023? Yeah, Casey. You know, I think, you know, as we talked about from a guidance perspective, obviously we don't provide, you know, specific business unit guidance. You know, that said, you know, we have seen kind of a general trend. You know, a lot of companies right now are in cash preservation mode. When we look at, you know, companies across our customer spectrum, you know, we think that many are bringing down inventory levels, you know, from a cash preservation standpoint. You know, I think it's tough to predict exactly, you know, when that's gonna end. You know, our guidance that we gave, you know, roughly on the call was that, you know, we would expect, you know, relatively, you know, similar trends here in the near term, but, you know, we're very optimistic longer term. You know, we're hoping to see some improvement as we go throughout the year for that business. We haven't provided, you know, specific business unit guidance. Okay, fair enough. My follow-up is just on the Quest partnership. How much upside does this provide in 2023? You know, can you give us a sense of how many tests a year you would be providing products for and, you know, how we should be modeling the impact to margins there? Thank you. Yeah, Casey, while we're not sharing specific details of it, what we would say is that, you know, as the preferred provider for Quest Genomic Sequencing Services Group, it's for all saliva collection for that business. We're obviously, you know, hoping and cheering for their launch. They will be, you know. We'll be hoping that that grows, and I think, you know, we'll be staying tuned. The opportunity, though, is, you know, for customers like Quest, and I'd say just this theme of moving to meet patients where they are, the beauty of our effortless sample collection is that we can power the entire industry in doing that. Our strategy is to increasingly be the go-to sample collection innovator across sample types. I think while it's a great example and we're, you know, rooting for them, we're really looking to be that partner across the whole industry. Thank you. I'm not showing any further questions in the queue. I would like to turn the call back over to Carrie for any closing remarks. Great. Thank you to each of you for joining. We appreciate the interest. you know, while we look here to 2023, we just emphasize that the shift from our strengthening the foundation and a very solid reset for our financial footing to elevating our core growth and allowing us to accelerate into profitable growth. More to come. Thank you again, and have a good night. This concludes today's conference call. Thank you for participating. You may now disconnect. Everybody, have a great day.